Archiv
Archiv anzeigen:
bis


Preventing Venous Thromboembolism with Direct Oral Anticoagulants

David Green, MD, PhD reviewing Tao DL et al. Blood 2016 Dec 20

A small reduction in thrombosis risk with DOAC, as compared with low-molecular-weight heparin, came at a cost of an increase in major bleeding.


Report from the 58th American Society of Hematology Annual Meeting — Malignant Hematology

Michael E. Williams, MD, ScM

Highlights of the latest research


The 2016 San Antonio Breast Cancer Symposium

William J. Gradishar, MD

Highlights of the latest research


Cancer Immunotherapy and New-Onset Rheumatic Symptoms: A Case Series

Jonathan S. Coblyn, MD reviewing Cappelli LC et al. Ann Rheum Dis 2017 Jan

Inflammatory arthritis or sicca syndrome symptoms can develop after starting treatment with immune checkpoint inhibitors.


Atezolizumab vs. Docetaxel for Pretreated Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Rittmeyer A et al. Lancet 2016 Dec 12

Overall survival was significantly improved with the PD-L1 inhibitor atezolizumab in a phase III study.


NEJM Journal Watch Oncology and Hematology Top Stories of 2016

William J. Gradishar, MD

A perspective on the most important research in the field from the past year


Should the Ovaries Be Spared at Hysterectomy for Early-Stage Cervical Cancer?

Andrew M. Kaunitz, MD reviewing Matsuo K et al. 2016 Dec 2

Large retrospective U.S. cohort analysis suggests so.


Onartuzumab for Pretreated Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Spigel DR et al. J Clin Oncol 2016 Dec 12

Adding onartuzumab to erlotinib significantly shortened overall survival.


Osimertinib for Patients with EGFR T790M–Positive Lung Cancer

Anne S. Tsao, MD reviewing Mok TS et al. N Engl J Med 2016 Dec 6

The EGFR inhibitor osimertinib is superior to chemotherapy and should be considered the standard of care for this population.


Regorafenib for Hepatocellular Carcinoma

David H. Ilson, MD, PhD reviewing Bruix J et al. Lancet 2016 Dec 5, Nault J-C. Lancet 2016 Dec 5

Regorafenib is the first agent to show a survival benefit for patients who progressed on sorafenib.


Archiv
Seite von 48
Editorial Member Board Empfehlungen

Prof. Dr. med. Florian Otto

Tumor- und Brustzentrum ZeTuP, St. Gallen

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Immuntherapie ist in aller Munde. Checkpoint-Inhibitoren werden bei praktisch allen onkologischen Erkrankungen erprobt und erweisen sich häufig als wirksam – zumindest für eine gewisse Zeit. Aber wie entwickelt sich eine Resistenz? Dieser Frage sind Zaretsky und Kollegen im Kontext von vier Melanompatienten unter Pembrolizumab-Therapie nachgegangen und haben Defekte im Interferon-Signalweg sowie der Antigenpräsentation in den Tumorzellen gefunden.

Kommentar weiterlesen

Management of Localized Prostate Cancer: Data at Last

Robert Dreicer, MD, MS, FACP, FASCO reviewing Hamdy FC et al. N Engl J Med 2016 Sep 14, D'Amico AV. N Engl J Med 2016 Sep 14

Mortality was similar with active monitoring, prostatectomy, or radiotherapy during 10 years of follow-up.


Hereditary Thrombophilia and Risk for Pregnancy-Associated Venous Thromboembolism

David Green, MD, PhD reviewing Gerhardt A et al. Blood 2016 Sep 9

Pregnant women with inherited thrombophilia have increased risk for VTE, independent of a family history of VTE.


Little Benefit to Extensive Breast Cancer Monitoring

William J. Gradishar, MD reviewing Accordino MK et al. J Clin Oncol 2016 Aug 20, Smith KL and Smith TJ. J Clin Oncol 2016 Aug 20

The use of >12 serum tumor marker tests and/or 4 radiographic imaging tests per year provided no survival advantage.


FOLFOX Equals or Betters Epirubicin, Cisplatin, and Fluorouracil in Esophagogastric Cancer

David H. Ilson, MD, PhD reviewing Enzinger PC et al. J Clin Oncol 2016 Aug 10

Adding epirubicin to fluorouracil/platinum-based chemotherapy resulted in greater toxicity and no clear improvement in response.


Reversing Anticoagulant-Associated Bleeding with Andexanet

David Green, MD, PhD reviewing Connolly SJ et al. N Engl J Med 2016 Aug 30

Andexanet reduced anti–factor Xa activity and restored effective hemostasis in patients with major bleeding.


Another Tool to Help Breast Cancer Patients Avoid Chemotherapy

William J. Gradishar, MD reviewing Cardoso F et al. N Engl J Med 2016 Aug 25, Hudis CA and Dickler M. N Engl J Med 2016 Aug 25

A 70-gene signature identified patients with high clinical risk and low molecular risk who achieved a 5-year survival rate of 94.7% without chemotherapy.


Daratumumab for Advanced Light Chain Amyloidosis

David Green, MD, PhD reviewing Sher T et al. Blood 2016 Aug 19

Declines in light chain levels were achieved in heavily pretreated patients.


HER2 a Potential Target in Colorectal Cancer

David H. Ilson, MD, PhD reviewing Sartore-Bianchi A et al. Lancet Oncol 2016 Jun

The HER2-targeted combination regimen of trastuzumab and lapatinib may have activity in HER2-positive, chemotherapy-refractory disease.


Resistance to Anti–PD-1 Therapy in Melanoma Patients

Jeffrey A. Sosman, MD reviewing Zaretsky JM et al. N Engl J Med 2016 Jul 13

Mutations preventing interferon-receptor signaling and antigen presentation are linked to acquired resistance.


Adjuvant S-1 for Resected Pancreatic Cancer

David H. Ilson, MD, PhD reviewing Uesaka K et al. Lancet 2016 Jun 2, Ko AH et al. Lancet 2016 Jun 2

Overall survival was significantly better with S-1 versus gemcitabine.